What is the gross margin for DXCM in 2021-Q1 
f you could talk about those, and specifically what those kinds of products, I'm thinking is there something outside of the regular hardware upgrades that we see maybe somewhere on the software side, that could be a catalyst maybe for growth within maybe some of the TAM expansion opportunities like the Type 2 non-intensives, or gestational diabetes or anything like that. So is there anything we're kind of not thinking out-of-the-box here from the normal hardware that will be important in the coming 12 months or so?
Jereme Sylvain -- Cheif Financial Officer
I don't think that there is anything that you guys are missing in terms of the prepared remarks and speaking to some of those systems. The one thing that we certainly are excited about, has to be the Omnipod 5 product in the back half of the year, and we'll let Insulet speak to the exact timing of when we're ready to put that product into the marketplace, but having connectivity into a product like that is something that we're very excited about and believe that they'll have success with and will have success with as well.
I think with respect to the whole Type 2 population and the opportunity there, we couldn't be more bullish on the opportunity that sits in front of us, and I think by the day we learn more-and-more of that increases that bullishness for us in the confidence that there's going to be some real opportunity there to create value coming from it, and you're going to see a study a little bit later this year, mid-year at some of the mid-year society meetings, that's going to start to really lay out the benefit of using CGM relative to BGM in this Type 2 population, particularly the non-intensive population that just demonstrates the sort of impact we can have on patients that are on basal only and that's a 4 million patient population in the U.S.
So I think that sort of data starts to really accumulate in favor of opening up a whole another market segment that doubles the existing core U.S. intensive market today that we're very excited about. So you'll see that data here, mid-year, but I think all of it starts to point to the fact that this Type 2 space is going to open up in a significant way and we are well-positioned to take advantage of it.
Operator
And that concludes the question-and-answer session. I will turn the call back over to Kevin Sayer for final remarks.
Kevin Sayer -- Chairman, President and Chief Executive Officer
Thank you, and thanks everybody for participating.
As we wrap up our call today, I want to take a minute to acknowledge some very important recognition that Dexcom received this week. Forbes recently published their 100 company list of America's Best Employers for Diversity. Dexcom was honored to be Number 66 on that list. While we consider this a perpetual journey, we're very happy to have been recognized for some of the work that we've done so far.
As far as our outlook on the business going forward our great quarter fuels, our continue believe that the best is yet to come. I recently caught up with a friend who is a longtime healthcare industry executive and the gist of his message to me was very simple, everything important in diabetes care is going to revolve around CGM. For example, there are numerous instant delivery devices and algorithms available for automated insulin delivery, but there is only one CGM commercially capable of delivering the patient experience and outcomes that we've all envisioned for a very long time, and that's only the beginning.
There are incredible new compounds, treatments and program stepping forward for the treatment of Type 2 diabetes and we are very confident that the right CGM experience will become an integral part of all these solutions and we haven't even started talking about the difference we can make as part of a pre-diabetes program. We've never been more excited and engaged in our opportunity than we are today.
Thank you again everyone and have a great day.
Operator
[Operator Closing Remarks]
Duration: 58 minutes
Call participants:
Sean Christensen -- Director of Corporate Affairs and 
f you could talk about those, and specifically what those kinds of products, I'm thinking is there something outside of the regular hardware upgrades that we see maybe somewhere on the software side, that could be a catalyst maybe for growth within maybe some of the TAM expansion opportunities like the Type 2 non-intensives, or gestational diabetes or anything like that. So is there anything we're kind of not thinking out-of-the-box here from the normal hardware that will be important in the coming 12 months or so?
Jereme Sylvain -- Cheif Financial Officer
I don't think that there is anything that you guys are missing in terms of the prepared remarks and speaking to some of those systems. The one thing that we certainly are excited about, has to be the Omnipod 5 product in the back half of the year, and we'll let Insulet speak to the exact timing of when we're ready to put that product into the marketplace, but having connectivity into a product like that is something that we're very excited about and believe that they'll have success with and will have success with as well.
I think with respect to the whole Type 2 population and the opportunity there, we couldn't be more bullish on the opportunity that sits in front of us, and I think by the day we learn more-and-more of that increases that bullishness for us in the confidence that there's going to be some real opportunity there to create value coming from it, and you're going to see a study a little bit later this year, mid-year at some of the mid-year society meetings, that's going to start to really lay out the benefit of using CGM relative to BGM in this Type 2 population, particularly the non-intensive population that just demonstrates the sort of impact we can have on patients that are on basal only and that's a 4 million patient population in the U.S.
So I think that sort of data starts to really accumulate in favor of opening up a whole another market segment that doubles the existing core U.S. intensive market today that we're very excited about. So you'll see that data here, mid-year, but I think all of it starts to point to the fact that this Type 2 space is going to open up in a significant way and we are well-positioned to take advantage of it.
Operator
And that concludes the question-and-answer session. I will turn the call back over to Kevin Sayer for final remarks.
Kevin Sayer -- Chairman, President and Chief Executive Officer
 Thank you, and thanks everybody for participating.
As we wrap up our call today, I want to take a minute to acknowledge some very important recognition that Dexcom received this week. Forbes recently published their 100 company list of America's Best Employers for Diversity. Dexcom was honored to be Number 66 on that list. While we consider this a perpetual journey, we're very happy to have been recognized for some of the work that we've done so far.
As far as our outlook on the business going forward our great quarter fuels, our continue believe that the best is yet to come. I recently caught up with a friend who is a longtime healthcare industry executive and the gist of his message to me was very simple, everything important in diabetes care is going to revolve around CGM. For example, there are numerous instant delivery devices and algorithms available for automated insulin delivery, but there is only one CGM commercially capable of delivering the patient experience and outcomes that we've all envisioned for a very long time, and that's only the beginning.
There are incredible new compounds, treatments and program stepping forward for the treatment of Type 2 diabetes and we are very confident that the right CGM experience will become an integral part of all these solutions and we haven't even started talking about the difference we can make as part of a pre-diabetes program. We've never been more excited and engaged in our opportunity than we are today.
Thank you again everyone and have a great day.
Operator
[Operator Closing Remarks]
Duration: 58 minutes
Call participants:
Sean Christensen -- Director of Corporate Affairs and 